CovidChloroV1, Main, Corpus, bibRecord, 000E13

Pandemic COVID-19: Current status and challenges of antiviral therapies.

Identifieur interne : 000E13 ( Main/Corpus ); précédent : 000E12; suivant : 000E14

Pandemic COVID-19: Current status and challenges of antiviral therapies.

Auteurs : Winglam Chan ; Betsy He ; Xiong Wang ; Ming-Liang He

Source :

Genes & diseases [ 2352-3042 ] ; 2020.

RBID : pubmed:32837984

Abstract

The pandemic COVID-19, caused by a new coronavirus SARS-CoV-2 infection, has infected over 12 million individuals and caused more than 55,200 death worldwide. Currently, there is no specific drug to treating this disease. Here we summarized the mechanisms of antiviral therapies and the clinic findings from different countries. Antiviral chemotherapies have been conducted by in multiple cohorts in different counties. Although FDA has fast approved remdesivir for treating COVID-19, it only speeds up recovery from COVID-19 with mildly reduced mortality. The chloroquine was suggested a potential drug against SARS-CoV-2 infection due to its in vitro antiviral effects, it is imperative high-quality data from worldwide clinical trials are necessitated for an approved therapy. In terms of hydroxychloroquine (HCQ) therapy, although WHO has stopped all the clinic trials due to its strong side-effects in COVID patients, large scale clinical trials with a long-term outcome follow-up may warrant HCQ and azithromycin combination in combating the virus. Convalescent plasma (CP) therapy suggested its safety use in SARS-CoV-2 infection; but both CP immunotherapy and NK cellular therapy must be manufactured and utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human origin. Further research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis, suitable animal models or ex vivo human lung tissues aid in studying replication, transmission and spread of the novel viruses, thereby facilitating highly effective therapies.

DOI: 10.1016/j.gendis.2020.07.001
PubMed: 32837984
PubMed Central: PMC7340039

Links to Exploration step

pubmed:32837984

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pandemic COVID-19: Current status and challenges of antiviral therapies.</title>
<author><name sortKey="Chan, Winglam" sort="Chan, Winglam" uniqKey="Chan W" first="Winglam" last="Chan">Winglam Chan</name>
<affiliation><nlm:affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="He, Betsy" sort="He, Betsy" uniqKey="He B" first="Betsy" last="He">Betsy He</name>
<affiliation><nlm:affiliation>Rensselaer Polytechnic Institute, Troy, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Xiong" sort="Wang, Xiong" uniqKey="Wang X" first="Xiong" last="Wang">Xiong Wang</name>
<affiliation><nlm:affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="He, Ming Liang" sort="He, Ming Liang" uniqKey="He M" first="Ming-Liang" last="He">Ming-Liang He</name>
<affiliation><nlm:affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>CityU Shenzhen Research Institute, Nanshan, Shenzhen, China.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32837984</idno>
<idno type="pmid">32837984</idno>
<idno type="doi">10.1016/j.gendis.2020.07.001</idno>
<idno type="pmc">PMC7340039</idno>
<idno type="wicri:Area/Main/Corpus">000E13</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E13</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pandemic COVID-19: Current status and challenges of antiviral therapies.</title>
<author><name sortKey="Chan, Winglam" sort="Chan, Winglam" uniqKey="Chan W" first="Winglam" last="Chan">Winglam Chan</name>
<affiliation><nlm:affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="He, Betsy" sort="He, Betsy" uniqKey="He B" first="Betsy" last="He">Betsy He</name>
<affiliation><nlm:affiliation>Rensselaer Polytechnic Institute, Troy, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Xiong" sort="Wang, Xiong" uniqKey="Wang X" first="Xiong" last="Wang">Xiong Wang</name>
<affiliation><nlm:affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="He, Ming Liang" sort="He, Ming Liang" uniqKey="He M" first="Ming-Liang" last="He">Ming-Liang He</name>
<affiliation><nlm:affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>CityU Shenzhen Research Institute, Nanshan, Shenzhen, China.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Genes & diseases</title>
<idno type="eISSN">2352-3042</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pandemic COVID-19, caused by a new coronavirus SARS-CoV-2 infection, has infected over 12 million individuals and caused more than 55,200 death worldwide. Currently, there is no specific drug to treating this disease. Here we summarized the mechanisms of antiviral therapies and the clinic findings from different countries. Antiviral chemotherapies have been conducted by in multiple cohorts in different counties. Although FDA has fast approved remdesivir for treating COVID-19, it only speeds up recovery from COVID-19 with mildly reduced mortality. The chloroquine was suggested a potential drug against SARS-CoV-2 infection due to its <i>in vitro</i>
 antiviral effects, it is imperative high-quality data from worldwide clinical trials are necessitated for an approved therapy. In terms of hydroxychloroquine (HCQ) therapy, although WHO has stopped all the clinic trials due to its strong side-effects in COVID patients, large scale clinical trials with a long-term outcome follow-up may warrant HCQ and azithromycin combination in combating the virus. Convalescent plasma (CP) therapy suggested its safety use in SARS-CoV-2 infection; but both CP immunotherapy and NK cellular therapy must be manufactured and utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human origin. Further research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis, suitable animal models or <i>ex vivo</i>
 human lung tissues aid in studying replication, transmission and spread of the novel viruses, thereby facilitating highly effective therapies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32837984</PMID>
<DateRevised><Year>2021</Year>
<Month>04</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3042</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>7</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Genes & diseases</Title>
<ISOAbbreviation>Genes Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Pandemic COVID-19: Current status and challenges of antiviral therapies.</ArticleTitle>
<Pagination><MedlinePgn>502-519</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gendis.2020.07.001</ELocationID>
<Abstract><AbstractText>The pandemic COVID-19, caused by a new coronavirus SARS-CoV-2 infection, has infected over 12 million individuals and caused more than 55,200 death worldwide. Currently, there is no specific drug to treating this disease. Here we summarized the mechanisms of antiviral therapies and the clinic findings from different countries. Antiviral chemotherapies have been conducted by in multiple cohorts in different counties. Although FDA has fast approved remdesivir for treating COVID-19, it only speeds up recovery from COVID-19 with mildly reduced mortality. The chloroquine was suggested a potential drug against SARS-CoV-2 infection due to its <i>in vitro</i>
 antiviral effects, it is imperative high-quality data from worldwide clinical trials are necessitated for an approved therapy. In terms of hydroxychloroquine (HCQ) therapy, although WHO has stopped all the clinic trials due to its strong side-effects in COVID patients, large scale clinical trials with a long-term outcome follow-up may warrant HCQ and azithromycin combination in combating the virus. Convalescent plasma (CP) therapy suggested its safety use in SARS-CoV-2 infection; but both CP immunotherapy and NK cellular therapy must be manufactured and utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human origin. Further research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis, suitable animal models or <i>ex vivo</i>
 human lung tissues aid in studying replication, transmission and spread of the novel viruses, thereby facilitating highly effective therapies.</AbstractText>
<CopyrightInformation>© 2020 Chongqing Medical University. Production and hosting by Elsevier B.V.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Winglam</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Betsy</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Rensselaer Polytechnic Institute, Troy, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Xiong</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Ming-Liang</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CityU Shenzhen Research Institute, Nanshan, Shenzhen, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Genes Dis</MedlineTA>
<NlmUniqueID>101635967</NlmUniqueID>
<ISSNLinking>2352-3042</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Chloroquine</Keyword>
<Keyword MajorTopicYN="N">Convalescent plasma therapy</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">Ivermectin</Keyword>
<Keyword MajorTopicYN="N">Natural killer cell therapy</Keyword>
<Keyword MajorTopicYN="N">Remdesivir</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
</KeywordList>
<CoiStatement>All authors declare no conflicts of interests.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32837984</ArticleId>
<ArticleId IdType="doi">10.1016/j.gendis.2020.07.001</ArticleId>
<ArticleId IdType="pii">S2352-3042(20)30083-0</ArticleId>
<ArticleId IdType="pmc">PMC7340039</ArticleId>
</ArticleIdList>
<pmc-dir>pmcsd</pmc-dir>
        <ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19321428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Microbiol. 2020 Apr;5(4):536-544</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32123347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2015 Jul;3(7):554-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26041403</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2008 May;9(5):495-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18425106</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Apr;84(7):3134-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19906932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Mar 13;367(6483):1260-1263</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Ophthalmol. 2011;5:1479-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22069350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2005 Feb;75(2):185-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15602737</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2011 Feb 15;52(4):447-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21248066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Apr 11;395(10231):1225-1228</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32178769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2017 Jan;27(1):119-129</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28008928</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 1996 Oct;31(4):257-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8896943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Acad Dermatol. 2020 Jun;82(6):e221</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283237</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2017 Sep 13;8:1124</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28955340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 May 05;6:25359</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27146253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32663409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2017 Aug 24;61(9):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28839081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 2002 Oct;32(10):2881-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12355441</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eye (Lond). 2020 Jul;34(7):1155-1157</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32029919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hong Kong Med J. 2006 Dec;12(6):489</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17148811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2005 Oct;77(2):147-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16121363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine. 2018 Apr;104:8-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29414327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):11-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6408923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2015 Jul 27;6:368</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26284063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Anal. 2020 Apr;10(2):102-108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32282863</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Infect Dis. 2015 Jul 10;1(7):317-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27622822</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Sep;99(3):301-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23769930</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25073113</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2015 Feb;45(2):428-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25359346</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Springerplus. 2015 Nov 19;4:709</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26618098</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1997 Jan;71(1):267-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8985346</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2008 Feb;77(2):150-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18055026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2006 Oct 17;145(8):599-609</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2015 Dec;41:3-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26482389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2018 Aug;19(8):800-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30026479</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 2020 Jun;41(6):363-382</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32291112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem J. 2012 May 1;443(3):851-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22417684</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Rheumatol. 2013 Aug;19(5):286-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23872551</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2019 May 28;10(1):2342</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31138817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Sep 13;357(11):1162-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17855683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2017 Mar;74(3):302-309</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27867062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Entomol. 2008 Jan;45(1):75-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18283945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32141570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Sep;79(17):11507-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16103202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inflammopharmacology. 2015 Oct;23(5):231-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26246395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1987 Feb 15;138(4):1064-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3027168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11157-11162</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29073020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2014 Nov 15;384(9956):1766-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25078306</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2020 Apr 10;295(15):4773-4779</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2016 May 20;352(6288):1001-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27199430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):398-400</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32113510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Virus Res. 2019;105:93-116</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31522710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 2010 Apr;40(4):923-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20209503</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 Apr 1;130(4):1545-1548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30070331</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2004 Feb;75(2):163-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14525967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Disaster Med Public Health Prep. 2020 Aug;14(4):506-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32207674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jun;178:104787</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2016 Sep;22(9):1554-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27532807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1998 Jun;72(6):4825-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9573248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Immunol. 2005 Feb;42(4):501-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15607806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Jun;7(6):439-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19430490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chembiochem. 2020 Mar 2;21(5):730-738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2020 May 01;11:827</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32425950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Host Microbe. 2020 Mar 11;27(3):325-328</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32035028</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Jun 26;368(6498):1499-1504</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32358203</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2018;23(7):617-622</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29923831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2007 May 10;361(2):304-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17210170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>One Health. 2020 Mar 27;9:100128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32258351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2017 Apr 10;8:15092</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28393837</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2006 May;34(5 Suppl):S118-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16617255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 16;382(16):1564-1567</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32182409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Sep 12;71(6):1400-1409</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32270184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2002 May 17;296(5571):1323-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11950999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Haematol. 2009 Nov;147(4):431-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19663827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2007 Apr 15;195(8):1108-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17357046</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1996 Feb 1;156(3):1138-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8557990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine Growth Factor Rev. 2004 Oct;15(5):367-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15450252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Mol Biol. 2015;1282:1-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25720466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 May 09;6:25428</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27156930</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2011 May 10;413(2):265-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21435673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Pathol. 2005 Mar;36(3):303-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15791576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2019 Feb 21;176(5):1026-1039.e15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30712865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Mar 28;368(13):1251-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23534565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Today. 2020 Apr;25(4):668-688</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32006468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 May 4;49(9):2845-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16640347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 May;177:104760</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32135219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Dermatol. 2005 Jan;141(1):76-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15655146</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E13 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000E13 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32837984
   |texte=   Pandemic COVID-19: Current status and challenges of antiviral therapies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32837984" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Pandemic COVID-19: Current status and challenges of antiviral therapies.

Pandemic COVID-19: Current status and challenges of antiviral therapies.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki